Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study

https://doi.org/10.1016/S0360-3016(96)00602-5Get rights and content

Abstract

Purpose: The development of conformal radiation technique including improved patient immobilization has allowed us to test the value of dose escalation in optimizing the radiation treatment of prostate cancer.

Methods and Materials: Outcome is reported for 233 consecutive patients treated with conformal technique between March 1989 and October 1992. Dose was escalated from 68 Gy to 79 Gy. Patient status is reported at 3 years follow-up, which is available in all alive patients. Pretreatment and serial posttreatment prostate specific antigen (PSA) values are available for all patients. Pretreatment and serial post >1.5 ngm/ml and rising on two consecutive measures. Dose response for bNED control of cancer and late morbidity are represented by logit response models fitted to the data. Kaplan-Meier methods, the log rank test, and Cox Regression models are also used.

Results: No dose response is observed for bNED survival for patients with pretreatment PSA <10 ngm/ml comparing patients treated above or below 71.5 Gy or on multivariate analysis. Dose response is observed for bNED survival for pretreatment PSA groups of 10–19.9 ngm/ml. The dose associated with 50% bNED survival at 3 years is 64 Gy and 76 Gy, respectively. The slope of the dose responses are 13 and 9%, respectively. Dose response is demonstrated for Grade 2 gastrointestinal (GI), Grade 2 genitourinary (GU), and Grade 3,4 combined GI and GU late morbidity. The slopes of the morbidity resposnes are steeper than for cancer control (19 to 21%).

Conclusions: Patients with pretreatment PSA <10 nmg/ml do not benefit from dose escalation, and the serious late morbidity of conformal radiation at 70 Gy is <3%. Patients with PSA values 10–19.9 ngm/ml and 20+ ngm/ ml benefit from dose escalation beyond 70 Gy. Treatment beyond 75 Gy results in >10% serious morbidity unless special precautions are taken to protect the rectal mucosa. All levels of severity of radiation morbidity show a dose response and combined with the dose response for bNED survival these data allow the optimization of treatment.

References (34)

  • H. Sandler et al.

    3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients

    Int. J. Radiat. Oncol. Biol. Phys.

    (1993)
  • H.M. Sandler et al.

    Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy

    Radiother. Oncol.

    (1992)
  • G.K. Zagars et al.

    Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome

    Urol

    (1995)
  • M. Zelefsky et al.

    Early observations of acute and chronic toxicity and PSA response in patients with carcinoma of the prostate treated on a dose escalation study with 3D-CRT

    Int. J. Radiat. Oncol. Biol. Phys.

    (1994)
  • C.C. Boring et al.

    Cancer statistics, 1994

    CA Cancer J. Clin.

    (1994)
  • G.W. Chodak et al.

    Results of conservative management of clinically localized prostate cancer

    N. Engl. J. Med.

    (1994)
  • G.E. Hanks et al.

    Patterns of failure analysis of patients with high pretreatment PSA treated by radiation therapy: The need for improved systemic and loco-regional treatment

    J. Clin. Oncol.

    (1996)
  • Cited by (156)

    • Radical external beam radiotherapy for clinically localized prostate cancer in Japan: Changing trends in the patterns of care process survey

      2011, International Journal of Radiation Oncology Biology Physics
      Citation Excerpt :

      US PCS results indicate that many prostate cancer patients have been routinely treated with total doses of >70 Gy in the United States (25, 28). The use of increasing radiation doses in Japan might reflect the widespread dissemination of clinical trial results (32–35) and also a growing acceptance by radiation oncologists and urologists that radical EBRT is effective for treating prostate cancer (30, 31). Results of the current study indicate that hormone therapy was commonly used in conjunction with radiotherapy during the survey period in Japan.

    • Genitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined With Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose-Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity

      2009, International Journal of Radiation Oncology Biology Physics
      Citation Excerpt :

      Because a dose–response relationship has been shown for prostate cancer, particularly in patients with intermediate-risk prostate cancer (1, 2), dose escalation trials have been performed for localized prostate cancer, and improved local control has been reported (3, 4).

    • Combined Hypofractionated Radiation and Hormone Therapy for the Treatment of Intermediate-Risk Prostate Cancer

      2008, International Journal of Radiation Oncology Biology Physics
      Citation Excerpt :

      There is a supposition that conventional doses of radiation (70.2–72 Gy in 1.8- to 2-Gy fractions) may be inadequate and that further treatments may be required (22). Some have proposed dose escalation to 76–78 Gy as a solution (23–25), whereas others prefer the use of standard radiation doses with the adjunct of hormone therapy. Androgen ablation causes tumor regression by inhibiting DNA synthesis and proliferation of androgen-dependent cancer cells (26).

    View all citing articles on Scopus
    1

    Present address of B. E. Epstein: Vanderbilt Hospital, Nashville, TN

    View full text